


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
IMNM
Immunome
$22.64
Strengths

Upgraded on attractively valued
IMNM Price Performance
$18.13 (+24.88%)
$9.39 (+141.11%)
$11.24 (+101.42%)
$10.28 (+120.23%)
IMNM has Extreme risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

High volatilty

IMNM overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum
Activity
Activity
Future
Future
![]()
IMNM Analysts opinion is negative but has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential
IMNM Street Sentiment is extremely bullish and have negative views on the near-term outlook
Average key support and resistance price levels
Login to displayWhat is IMNM current stock price?
What are IMNM stock strengths?
What is IMNM Risk Level?
What is IMNM market cap and volume?
What is IMNM current Stock IQ?
Should I buy IMNM stock right now?
Is IMNM a Strong Buy right now?
What does a 'Strong Buy' rating mean for IMNM?
What does a 'Strong Sell' rating mean for IMNM?
What factors influence IMNM's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
IMNM
Immunome
Current Price
$22.64
Stock Insights
Strengths

Upgraded on attractively valued

IMNM Price Performance
$18.13 (+24.88%)
$9.39 (+141.11%)
$11.24 (+101.42%)
$10.28 (+120.23%)
IMNM Analysts Opinion
IMNM Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum
Activity
Activity
Future
Future
![]()
IMNM Analysts opinion is negative but has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential
IMNM Street Sentiment is extremely bullish and have negative views on the near-term outlook
IMNM has Extreme risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

High volatilty

Average key support and resistance price levels
IMNM Stock IQ
IMNM Latest Analysis
Immunome Stock Surges 20% After Positive Phase 3 Data For Desmoid Tumor Drug . (RTTNews) - Immunome Inc. (IMNM) shares jumped 20.44% rising $4.00 to close at $23.57 following the companys announcement of positive topline results from its Phase 3 RINGSIDE trial evaluating varegacestat in patients with desmoid tumors.
Today
Immunome A Top 3% Stock Just Delivered A Knockout To Merck KGaA. Top-notch biotech stock Immunome rocketed Monday after the companys treatment for desmoid tumors appeared to top an approved drug.The post Immunome A Top 3% Stock Just Delivered A '.Knockout'. To Merck KGaA appeared first on Investor'.s Business Daily.
Today
Why Is Immunome Stock Soaring Monday?. IMNM) stock rose Monday with session volume surging to 8.25 million shares well above the stock’.s average daily volume of 1.50 million according to data.Immunome on Monday shared topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat for .A desmoid tumor also known as aggressive fibromatosis is a rare noncancerous growth in connective tissue often in the abdomen arms or legs that is locally aggressive (infiltrates surrounding
Today
Immunomes Varegacestat Meets Phase-3 Endpoints In Desmoid Tumors- Update . (RTTNews) - Immunome Inc. (IMNM) Monday reported positive data from its pivotal Phase-3 RINGSIDE trial in patients with desmoid tumors with Varegacestat improving progression-free survival and meeting all key secondary endpoints.
Today
Truist Securities Initiates Coverage of Immunome (IMNM) with Buy Recommendation. Fintel reports that on December 1 2025 Truist Securities initiated coverage of Immunome (NasdaqCM:IMNM) with a Buy recommendation. Analyst Price Forecast Suggests 32.90% Upside
Mon Dec 1, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
IMNM Stock trends
IMNM Stock performance
IMNM Stock analysis
IMNM investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.